Mirum Pharmaceuticals
MIRM
58 hedge funds and large institutions have $366M invested in Mirum Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 5 closing their positions.
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
41% more capital invested
Capital invested by funds: $260M → $366M (+$106M)
35% more funds holding
Funds holding: 43 → 58 (+15)
0.8% more ownership
Funds ownership: 73.28% → 74.08% (+0.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5M |
| 2 |
BlackRock
New York
|
+$2.82M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$2.06M |
| 4 |
Morgan Stanley
New York
|
+$1.65M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
-$10.8M |
| 2 |
Millennium Management
New York
|
-$1.41M |
| 3 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$969K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$958K |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$754K |
MIRM Hedge Fund Activity: Q2 2020 in Review
58 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q2 2020, worth a combined $366M — up 41% from $260M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new MIRM positions and 5 closed out — a net gain of 15 holders — while 16 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $5M. The largest seller was Polar Capital, exiting entirely with an estimated $10.8M sold.
- 58 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q2 2020, up from 43 in Q1 2020.
- Funds reported $366M of Mirum Pharmaceuticals stock for Q2 2020, up 41% quarter-over-quarter.
- 20 funds opened new Mirum Pharmaceuticals positions in Q2 2020 and 5 closed out, a net change of +15 holders.
- The largest Mirum Pharmaceuticals buyer in Q2 2020 was Vanguard Group, an estimated $5M added.
- The largest Mirum Pharmaceuticals seller in Q2 2020 was Polar Capital, an estimated $10.8M sold.
Based on aggregated 13F filings for Q2 2020.